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Abstract Human cytomegalovirus has hijacked and evolved a human G-protein-coupled receptor
into US28, which functions as a promiscuous chemokine ’sink’ to facilitate evasion of host immune
responses. To probe the molecular basis of US28’s unique ligand cross-reactivity, we deep-
sequenced CX3CL1 chemokine libraries selected on ‘molecular casts’ of the US28 active-state and
find that US28 can engage thousands of distinct chemokine sequences, many of which elicit diverse
signaling outcomes. The structure of a G-protein-biased CX3CL1-variant in complex with US28
revealed an entirely unique chemokine amino terminal peptide conformation and remodeled
constellation of receptor-ligand interactions. Receptor signaling, however, is remarkably robust to
mutational disruption of these interactions. Thus, US28 accommodates and functionally
discriminates amongst highly degenerate chemokine sequences by sensing the steric bulk of the
ligands, which distort both receptor extracellular loops and the walls of the ligand binding pocket
to varying degrees, rather than requiring sequence-specific bonding chemistries for recognition
and signaling.
DOI: https://doi.org/10.7554/eLife.35850.001
Introduction
Chemokines are small immunomodulatory proteins that act through a large family of G-protein-cou-
pled receptors (GPCR) (Charo and Ransohoff, 2006; Proudfoot, 2002). More than 40 chemokines
and over 20 chemokine receptors are encoded in the human genome, and there is extensive recep-
tor-ligand cross-reactivity, which can manifest as preferential signaling via either G protein or b-
arrestin, a process called biased agonism (Steen et al., 2014). Human cytomegalovirus (CMV) has
‘hijacked’ a relatively ligand-specific human GPCR, and repurposed it through evolution to serve as
a highly cross-reactive ‘chemokine sink’ as a mechanism to subvert host immunity (Randolph-
Habecker et al., 2002). US28 binds with high affinity to many CC-type chemokines, in addition to
CX3CL1 (Kledal et al., 1998). The molecular mechanisms for how US28 can engage and respond to
such a wide range of chemokines are not understood; indeed, most receptor-ligand interactions are
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characterized by a high degree of specificity. Furthermore, it remains unclear to what extent, and
how, US28 has the capacity to signal differentially in response to these chemokines.
A crystal structure of CX3CL1 bound to US28 (Burg et al., 2015) showed that the chemokine
bound through a two-site interaction mechanism (Allen et al., 2007; Monteclaro and Charo, 1996;
Thiele and Rosenkilde, 2014) that is generally shared by other chemokine GPCRs (Wu et al., 2010;
Wescott et al., 2016; Zheng et al., 2017). At Site 1, the receptor N-terminal region binds a groove
on the globular body of the chemokine. At Site 2, the chemokine N-terminal peptide binds within a
deep pocket formed by the receptor transmembrane helices (TMs) that is believed to function as the
receptor activation switch. The structure also revealed extensive contacts with receptor extracellular
loops (ECLs), coined Site 1.5, of unknown function. Given that US28 has a unique capacity to bind
many diverse chemokines with high affinity (Kledal et al., 1998), we sought to determine: 1- the
breadth of ligand promiscuity that can be accommodated, 2- how sequence differences impact sig-
naling, and 3- the structural properties of this interaction that enable such cross-reactivity.
Results and discussion
Chemokine-induced US28 signaling
Radioligand studies reveal a complex network of noncompetitive binding by these chemokines
(Figure 1a). Whereas CX3CL1 (Fractalkine) and vMIP-II (a broad-spectrum CC-chemokine antagonist
encoded by Kaposi’s sarcoma-associated herpes virus (KSHV) [Kledal et al., 1997]), bind US28 com-
petitively, CCL3 (MIP1a) and CCL5 (RANTES) are only competitive with themselves. This manner of
‘orthosteric allostery’ is well established among chemokine receptor antagonists and suggests signif-
icant differences in the nature of receptor engagement, with the potential for differences in chemo-
kine modulation of US28 activity (Kufareva et al., 2017). Although isolated studies have attempted
to delineate the signaling effects of individual chemokines at US28, no comprehensive effort has
been made to compare chemokine-induced activity among US28’s many ligands or to determine
whether they act as biased ligands. US28 signals constitutively via the G protein Gq (Casarosa et al.,
2001), and cells expressing US28 exhibit constitutive cell migration (Streblow et al., 1999), which is
thought to principally occur through b-arrestin signaling (DeFea, 2007). We sought to establish the
capacity of natural and chimeric chemokine ligands of US28 to modulate this constitutive activity.
We tested CX3CL1, CCL5, CCL3, and vMIP-II, as well as N-terminal chimeric chemokines, for their
effects on Gq-mediated calcium flux and cell migration, which serves as a proxy for b-arrestin
signaling.
These chemokines (four natural and two chimeric) produce a broad range of ligand-induced sig-
naling activities, on top of the receptors’ constitutive activity. The high levels of constitutive signaling
and b-arrestin recruitment (Figure 1b and d) complicate precise quantitation and leave a narrow
dynamic range in which to directly observe ligand effects, but nevertheless we were able to detect
significant changes in US28 activity upon addition of chemokine. Comparing Gq-mediated calcium
flux and migration responses, we find that US28 is capable of highly plastic but ligand-specific signal-
ing activities that qualitatively suggest capacity for biased signaling (Figure 1c and e and Figure 1—
figure supplements 1 and 2). vMIP-II binds US28 with high affinity while having no effect on the
receptor’s activity, acting as a neutral antagonist (Figure 1c and e and Figure 1—figure supple-
ment 3). CCL3 increases Ca2+ signaling while migration remains unaffected, thus appearing to be a
G-protein-biased agonist. CCL5 and CX3CL1 potentiate both Ca2+ signaling and cell migration, with
CX3CL1 exhibiting more prominent cell migration. Despite prior reports of Gq inverse agonism by
CX3CL1 (Tschammer, 2014; Waldhoer et al., 2003), we observe US28-mediated CX3CL1 inverse
agonism only in IP3 assays with COS-7 cells (Figure 1b). Chimeric chemokines in which the globular
body of CX3CL1 was appended to the N-terminus of vMIP-II (NVF) or CCL5 (N5F) displayed weak
calcium flux and moderate cell migration, diminishing the effects of CCL5 while converting vMIP-II
from an antagonist to an agonist (Figure 1c and e). It is unclear whether this signaling behavior
arises from direct contacts by the chemokine globular body or indirect contacts that arise from the
manner in which the globular body drapes the chemokine N-terminus within the receptor binding
pocket. The chemokine N-terminus thus serves an instructive, although not solely determinative, role
in dictating signaling through US28. In sum, these studies establish the plasticity of ligand-depen-
dent US28 signaling.
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Figure 1. Natural and chimeric chemokines are agonists for US28. (a) Radioligand binding competition experiments with labeled CX3CL1, CCL3, and
CCL5. (b) CX3CL1-induced IP3 turnover is US28 and cell type specific. Dotted line indicates US28 basal activity; all statistics are relative to this. (c) US28-
induced calcium responses of 100 nM natural and chimeric chemokines. Dotted line indicates US28 basal activity; all statistics are relative to this. (d)
US28 basal b-arrestin recruitment leaves narrow dynamic range in which to observe ligand effects. (e) Migration effects of 100 nM natural and chimeric
Figure 1 continued on next page
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The sequence space of chemokine agonism
We next explored the structural diversity of chemokine N-terminal sequences compatible with US28
engagement to uncover sequence hallmarks that correlate with particular signaling pathways and
downstream functions, such as induction of cell migration. We used a yeast-displayed library of
diverse chemokine variants to map the sequence specificity of receptor engagement and activation
by the Site 2 N-terminal peptide. Single chain fusions of US28 with intracellularly directed
nanobodies (Burg et al., 2015) (Nb7 or Nb11) enable purification of stable, apo-US28 (Figure 2—
figure supplement 1) that can be used to stain yeast cells displaying chemokine on their surface
(Figure 2a), thereby solving the general problem of structural instability of GPCRs purified in apo
form (Handel, 2015; Rosenbaum et al., 2009; Wu et al., 2010). The alpaca nanobodies were raised
against the US28/CX3CL1 complex, and, importantly, structures of CX3CL1-bound US28 with and
without Nb7 reveal no significant differences in receptor conformation. This confirms that the nano-
body does not deform US28 but merely selects a subset of pre-existing, stable, active-like conforma-
tions. Thus, these nanobody fusions serve as ‘molecular casts’ with which to screen yeast displayed
chemokine libraries using purified recombinant US28. Interestingly, we found that the two nanobod-
ies endow US28 with different chemokine binding pharmacologies: US28Nb7 was permissive for
binding of all tested chemokines, whereas US28Nb11 showed impaired binding of CCL5 and CCL3
(Figure 2b). This finding conforms with radioligand competition experiments and suggests that the
two nanobodies are stabilizing partially non-overlapping US28 conformational subsets.
A version of US28Nb7 was created that deletes the receptor N-terminus, thereby precluding Site
1 interaction with chemokines. Surprisingly, CX3CL1 and CCL5 show virtually unchanged affinity in
the absence of Site 1 interaction (Figure 2—figure supplement 2). This result stands in contrast to
analogous experiments in the absence of nanobody (Casarosa et al., 2005) and suggests that nano-
body7 selectively potentiates the affinity of CCL5 and CX3CL1 for US28 via Site 2, as has been
observed in other GPCRs (Staus et al., 2016).
Having seen the importance of Site 2 for US28Nb7 engagement, a CX3CL1 library was con-
structed in which the seven N-terminal residues of the chemokine were randomized (Figure 2—fig-
ure supplement 3). This library was displayed on the surface of yeast and selected with increasing
stringency for affinity to each of the nanobody-stabilized receptors (Figure 2c). Following selection,
the remaining pools of yeast were deep-sequenced to identify CX3CL1 sequences compatible with
binding either US28Nb7 or US28Nb11. This sequencing data showed that tens of thousands of
unique chemokine N-termini are able to bind US28 with high affinity (Figure 2d). While the
US28Nb11 selected chemokines appear slightly more converged, the most abundant unique variants
comprise only a small fraction of the total sequence count. To visualize these broad sequence land-
scapes, pairs of N-termini that differ at only one of the seven randomized residues were clustered;
to ensure significance we limited our analysis to sequences that appeared more than 10 times within
the pool. 794 unique US28Nb7-selected N-termini met these criteria, with each connected to an
average of 2.7 related sequences. Partitioning of these sequences into distinct subpopulations is not
observed. After US28Nb11 selection, 11,415 unique N-termini had at least one partner that differed
at only one position and each sequence connected to an average of 9.6 relatives.
Figure 1 continued
chemkines at US28. Dotted line indicates US28 basal activity; all statistics are relative to this. All data are given as mean ± s.e.m. of at least three
independent biological replicates. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 with respect to basal activity using one sample t-test, two-tailed.
DOI: https://doi.org/10.7554/eLife.35850.002
The following source data and figure supplements are available for figure 1:
Source data 1. Full statistics for wild type and chimeric chemokines.
DOI: https://doi.org/10.7554/eLife.35850.006
Figure supplement 1. Calcium signaling dose-response plots for wild type and chimeric chemokines.
DOI: https://doi.org/10.7554/eLife.35850.003
Figure supplement 2. Cell migration dose-response plots for wild type and chimeric chemokines.
DOI: https://doi.org/10.7554/eLife.35850.004
Figure supplement 3. vMIP-II antagonizes chemokine signaling via US28.
DOI: https://doi.org/10.7554/eLife.35850.005
Miles et al. eLife 2018;7:e35850. DOI: https://doi.org/10.7554/eLife.35850 4 of 23
Research article Biochemistry and Chemical Biology Structural Biology and Molecular Biophysics
Figure 2. CX3CL1 library reveals chemokine sequence promiscuity and biased agonism. (a) Illustration of yeast-displayed chemokine and nanobody-
stabilized receptors. (b) Effect of intracellular nanobody 7 or 11 on US28 binding to yeast-displayed chemokines. All data points are normalized to
binding at 1 mM US28Nb7 (c) Increase in binding at 1 nM US28 after selection with either US28Nb7 or US28Nb11. (d) Clustering of CX3CL1 N-terminal
sequences revealed by deep-sequencing after selection. Each point is a unique N-terminus and sequences sharing 6 of 7 amino acids are connected.
(e) Degree of amino acid convergence at each position of the CX3CL1 N-terminus. Amino acids with >3% abundance after selection are considered
allowed and the size of a shaded region corresponds to that amino acid’s frequency (PDB: 4xt1).
DOI: https://doi.org/10.7554/eLife.35850.007
The following source data and figure supplements are available for figure 2:
Source data 1. Unique CX3CL1 N-termini identified by deep sequencing after selection with US28Nb7 or US28Nb11.
DOI: https://doi.org/10.7554/eLife.35850.012
Figure supplement 1. US28-nanobody single chain constructs enable purification of apo-receptor.
DOI: https://doi.org/10.7554/eLife.35850.008
Figure supplement 2. Effects of US28Nb7 N-terminal deletion on yeast-displayed wild-type chemokine binding.
DOI: https://doi.org/10.7554/eLife.35850.009
Figure supplement 3. CX3CL1 ‘Site 2’ library design.
DOI: https://doi.org/10.7554/eLife.35850.010
Figure supplement 4. Effect of minimal chemokine Site 2 on US28Nb7 binding.
DOI: https://doi.org/10.7554/eLife.35850.011
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A residue-by-residue analysis of the combinatorial chemokine N-termini from the library selections
shows that sequence promiscuity extends along the full length of randomized positions (Figure 2e
and Figure 2—figure supplement 3). Despite this diversity, CX3CL1 with a polyglycine amino termi-
nus shows minimal binding to US28Nb7, confirming the necessity of certain N-terminal contacts (Fig-
ure 2—figure supplement 4). While the CX3CL1 wild type amino terminus appears in the
sequencing, the wild-type identity rarely emerges among the most abundant amino acids at a given
position. For example, hydrophobic amino acids enrich over the wild-type glutamine at position 1,
while arginine enriches over the wild-type histidine at position 2. As the same hydrophobic amino
acids score the worst in computational signal sequence cleavage site recognition, it is unlikely that
this result is simply due to biases in processing or expression (Nielsen, 2017).
A collection of highly diverse sequences was chosen from each of the two different nanobody
selections for further signaling characterization (Figure 3a and b and Figure 3—figure supplements
1 and 2). These chemokines bound US28Nb7 with affinities akin to wild-type CX3CL1 on yeast, yet
revealed comparatively weak competition with wild-type CX3CL1 in radioligand binding studies (Fig-
ure 3—figure supplement 3). This behavior is reminiscent to that of US28’s natural chemokine rep-
ertoire reported above. Because the high basal signaling of US28 results in a narrow dynamic range
in which to measure differences between agonists, we can only make qualitative conclusions about
signaling bias. Nevertheless, nearly all these chemokines induce some level of cell migration, though
none surpass that of wild-type CX3CL1 (Figure 3b). Conversely, G protein activation stronger than
wild-type CX3CL1 was elicited by LLPHANY (CX3CL1.35) (Figure 3a). To determine if the LLPHANY
sequence contained particular hallmark residues that correlate with G protein signaling, homologous
sequences to CX3CL1.35 that emerged from the deep sequencing were tested (Figure 3c and d).
These sequences include variants with mutations throughout the CX3CL1.35 N-terminus. Surpris-
ingly, despite the substantial sequence differences of these variants, most induced G protein signal-
ing in a qualitatively similar fashion to CX3CL1.35. Similarly, none of the CX3CL1.35 family members
showed significantly decreased cell migration. This result demonstrates that for a given ligand
sequence motif, signaling effects are relatively insensitive to individual sequence substitutions.
Structural basis for US28’s chemokine promiscuity
We determined the crystal structure of the US28 fusion to nanobody7 in complex with the engi-
neered chemokine CX3CL1.35 to 3.5 A˚ resolution (Figure 4a). Crystallization of the CX3CL1.35 com-
plex by Lipidic Cubic Phase required an additional nanobody, raised by alpaca immunization against
apo-US28Nb7 (Figure 4—figure supplement 1a,b). CX3CL1.35 contacts a symmetry-related nano-
body B1 (Figure 4—figure supplement 2a and b) raising the question of whether the native confor-
mation of the complex enables lattice contacts or, conversely, whether lattice contacts induce a non-
native conformational change in the complex. The former explanation is supported by the fact that
exhaustive attempts to crystallize other CX3CL1 library variants with US28Nb7 and nanobody B1 fail
to yield crystals.
The chemokine globular body sits atop the receptor in a very similar disposition as wild type
CX3CL1, albeit CX3CL1.35 is rotated by 16.8˚ (Figure 4a and Figure 4—figure supplement 3), con-
tributing to reduced interaction between the chemokine N-loop and US28 ECL2 (Figure 4—figure
supplement 4). This rotation is markedly greater than the 3˚ distortion in wild-type CX3CL1 bound
to US28 in structures with and without such lattice contacts (Burg et al., 2015)(Figure 4—figure
supplement 2c and d), further supporting the notion that this pose is not artefactual. The chemo-
kine N-termini trace markedly different paths within the ligand-binding pocket of US28 (Figure 4b,
Figure 4—figure supplement 5, and Figure 4—source data 1). The interaction chemistries and
structural environments for how CX3CL1 versus CX3CL1.35 engage US28 are distinct, with each che-
mokine occupying both overlapping and spatially segregated regions of the US28 orthosteric pocket
(Figure 4c). CX3CL1 forms extensive contacts with US28’s minor pocket at TM1, TM2, TM3, and
TM7 and ECL2 (Figure 4e and g). The N-terminus of CX3CL1.35 also fills the minor pocket sharing
contacts with Glu2777.39 (Figure 4d and f; Figure 4—source data 1), which is also commonly con-
tacted by small molecule chemokine ligands (Lu¨ckmann et al., 2017; Rosenkilde and Schwartz,
2006), as well as Trp892.60 and Phe1113.32 [superscripts refer to the Ballesteros-Weinstein
nomenclature (Ballesteros and Weinstein, 1995). Chemokine interaction at these three residues is
broadly conserved across receptors and strongly affects ligand affinity (Arimont et al., 2017).
Recent shotgun mutagenesis of CXCL12 with CXCR4 also implicates these residues in the initiation
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Figure 3. Signaling behavior or selected CX3CL1 library variants. (a) Calcium and, (b) migration responses of diverse chemokines revealed by deep
sequencing at 100 nM ligand. Dotted lines indicate wild-type CX3CL1 activity (red); all statistics are relative to this. CX3CL1.35, selected for further
study, is indicated in green. (c) Calcium and, (d) migration responses of CX3CL1.35-related sequences from deep sequencing at 100 nM ligand. Dotted
lines indicate CX3CL1.35 (green) activity; all statistics are relative to this. All data are given as mean ± s.e.m. of at least three independent biological
replicates. * p<0.05, ** p<0.01, *** p<0.001 by one-way ANOVA (Dunnett’s test).
DOI: https://doi.org/10.7554/eLife.35850.013
The following source data and figure supplements are available for figure 3:
Source data 1. Full statistics for selected CX3CL1 library variants.
DOI: https://doi.org/10.7554/eLife.35850.017
Figure supplement 1. Calcium signaling dose-response plots for selected CX3CL1 library variants.
DOI: https://doi.org/10.7554/eLife.35850.014
Figure supplement 2. Cell migration dose-response plots for selected CX3CL1 library variants.
DOI: https://doi.org/10.7554/eLife.35850.015
Figure supplement 3. Characterization of representative CX3CL1 library variants for receptor binding.
DOI: https://doi.org/10.7554/eLife.35850.016
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Figure 4. Crystal structure of US28 bound to engineered CX3CL1 and comparison with the wild-type chemokine. (a) CX3CL1.35-US28 and CX3CL1-
US28 structural alignment based on US28 transmembrane helices (PDB:4xt1). (b) Wild type and engineered chemokine N-termini trace different paths in
US28’s binding pocket. (c) Cutaway image of US28 with chemokine contacts highlighted for CX3CL1.35 (teal), CX3CL1 (purple), or both (yellow). (d)
CX3CL1.35 fills the entire binding pocket. (e) CX3CL1 hugs the TM2 side of US28. (f) US28 side chains contacted by CX3CL1.35 in the receptor binding
pocket. (g) US28 side chains contacted by CX3CL1 in the receptor-binding pocket.
DOI: https://doi.org/10.7554/eLife.35850.018
The following source data and figure supplements are available for figure 4:
Source data 1. CX3CL1.35 interactions with US28Nb7.
DOI: https://doi.org/10.7554/eLife.35850.024
Figure supplement 1. Nanobody B1 selections and binding interface.
DOI: https://doi.org/10.7554/eLife.35850.019
Figure supplement 2. Crystal packing of CX3CL1.35-US28Nb7-nanobody B1 complex structure.
DOI: https://doi.org/10.7554/eLife.35850.020
Figure supplement 3. US28 structural comparisons.
DOI: https://doi.org/10.7554/eLife.35850.021
Figure supplement 4. CX3CL1.35 ‘Site 1.5’ ECL2 contacts.
DOI: https://doi.org/10.7554/eLife.35850.022
Figure supplement 5. CX3CL1.35 ‘Site 2’ and receptor contacts.
DOI: https://doi.org/10.7554/eLife.35850.023
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of receptor signaling (Wescott et al., 2016). Unlike the wild-type chemokine, CX3CL1.35 also proj-
ects into the major pocket of the receptor toward TM5 and TM6, contacting Asn1895.39, Leu1925.42,
Tyr2446.51, Leu2486.55, and Asp2516.58 (Figure 4d and f). These residues superficially surround the
Trp2416.48 rotamer switch that is implicated in the transition between inactive and active GPCR
structures (Arimont et al., 2017; Latorraca et al., 2017). CX3CL1.35 loses the extensive direct con-
tacts to TM2 and ECL2 evident in the structure of the wild-type chemokine (Figure 4b and Fig-
ure 4—figure supplement 4). Indirect contacts between CX3CL1.35 and US28 ECL2 are mediated
by the sulfonate moiety of a MES ion from the crystallization buffer (Figure 4b).
Re-examining the signaling activity of the specific CX3CL1.35 sequence family members
(Figure 3c and d) in light of this structure demonstrates that signaling for either pathway is largely
unaffected by even drastic changes to the interactions within the receptor binding cavity. Calcium
signaling and migration are robust to disruption of receptor contacts throughout the binding pocket
suggesting either that specific side chain contacts are largely unimportant or that significant confor-
mational rearrangements of the chemokine amino terminus are made to preserve contacts. The
most prosaic explanation for the relative lack of sequence selectivity imposed by the US28 pocket,
yet ability of unrelated chemokine sequences to elicit differential signaling outputs, would be that
the steric bulk of the ligand is more important than specific bonding chemistries. If steric bulk, which
would apply strain to the walls of the US28 binding pocket, were the principal determinant of signal-
ing output, an almost unlimited number of sequences could elicit similar signaling outputs, which is
consistent with our data.
Extracellular rearrangements upon chemokine binding
To assess the impact of ligand binding on the structure and dimensions of the US28 ligand binding
pocket, we determined the crystal structure of apo-US28Nb7 without an extracellular ligand to 3.5 A˚
resolution (Figure 5—figure supplement 1a). Together, the CX3CL1-bound, CX3CL1.35-bound,
and apo-US28 structures allow direct comparisons among the basal and qualitatively b-arrestin- and
G-protein-biased states of the same GPCR, with the caveat that the bound nanobodies prevent us
from reaching conclusions about structural differences in the intracellular regions of US28 (Figure 5—
figure supplement 1b). In contrast to the chemokine-bound structures, access to the extracellular
binding cavity of US28 is significantly constricted in apo-US28, where ECL1 and ECL2 collapse
inward (Figure 5a). Each chemokine elicits distinct conformational changes in US28 in order to gain
access to the binding pocket. CX3CL1 displaces ECL1 and ECL2 away from the receptor core,
uncovering the binding pocket but causing minimal overall distortion (Figure 5b). Conversely,
CX3CL1.35 distorts TM1, TM6, and TM7 away from the receptor core, resulting in an expanded
binding pocket.
By way of comparison, small molecule agonists induce subtle contraction of the binding pocket,
drawing in TM5 (as in the ß2-adrenergic receptor [Rasmussen et al., 2011; Ring et al., 2013]), TM6
(as in the M2 muscarinic receptor [Kruse et al., 2013]), or TM3 (as in the m-opiod
receptor [Huang et al., 2015]) (Latorraca et al., 2017). Recent structures of endothelin B (ETb) sug-
gest that peptide agonists may behave more like chemokines. Apo and ET1-bound structures show
that activation results in large inward translations of the extracellular ends of TM6 and TM7 toward
TM3 (Shihoya et al., 2016).
The pronounced differences in ECL conformation and contacts with chemokine raise the possibil-
ity that chemokines may function as bitopic ligands via site 1.5 and site 2 interactions, with both
interaction sites working in concert to determine a chemokine’s precise signaling profile. This notion
is supported by the unique signaling profiles of chimeric chemokines NVF and N5F. ECL stabilization
is a common mechanism of allosteric modulation among group A GPCRs (Christopoulos, 2014;
Kruse et al., 2013) and recent mutagenesis studies suggest a role for ECL2 in chemokine receptor
signaling (Ziarek et al., 2017). Indeed, toggling ligand interactions between ECL2 and TM5 has
recently been proposed as a general mechanism of inducing signaling bias within aminergic class A
GPCRs (McCorvy et al., 2018).
Conclusions
Our approach using chemokine libraries has revealed that US28 can accommodate at least thou-
sands of chemically diverse chemokine N-termini, perhaps many more, indicating an astonishing
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Figure 5. Chemokine-dependent conformational changes in US28. (a) Top-down and side views of apo-, CX3CL1-, and CX3CL1.35-bound US28
showing expanded access to the receptor binding pocket when chemokine is present. (b) Structural alignment based on US28 transmembrane helices
showing unique US28 conformational changes caused by each chemokine. (PDB: 4xt1). Crystallographic data and refinement statistics are summarized
in Figure 5—source data 1.
Figure 5 continued on next page
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degree of ligand cross-reactivity for a cell surface receptor. Without apparent sequence patterns,
these engineered chemokines induce the full spectrum of signaling bias at US28. Natural chemokine
sequences merely represent a subset of local minima in a broad signaling fitness landscape. The
combined structural and deep sequencing data suggest that G protein activation is elicited as a con-
sequence of steric bulk distorting the walls the major pocket of the receptor, dilating the receptor’s
extracellular face, rather than highly specific and sequence-specific bonding chemistries. This relative
sequence-insensitive mechanism, which is highly unusual for protein-protein interactions, is likely
enabled by the N-terminal chemokine sequence binding within a capsule-shaped US28 pocket,
affording numerous opportunities for adventitious bonding interactions between the walls of the
pocket and alternative conformations of the N-terminal peptide. This is as opposed to the generally
broad and exposed interfaces seen in protein-protein interactions, which are generally much less tol-
erant to substitution. The properties exhibited by US28 explain how the virus evolved a human
GPCR to be highly promiscuous in order to promote viral survival and offer the broader possibility
that GPCR signaling can be activated by surrogate agonists that are unrelated to the natural ligands
and activate new signaling pathways.
Materials and methods
Key resources table
Reagent type
(species) or resource Designation Source or reference Identifiers Additional information
Gene
(human cytomegalovirus)
US28 (unique short region) PMID 7961796 strain TOWNE
Strain, strain
background
(Saccharomyces cerevisiae)
EBY100 Gift from Prof. Dane
Wittrup (PMID 17406305)
Yeast cells
Cell line
(Spodoptera frugiperda)
SF9 ATCC CTL-1711 Insect cells used for
baculovirus production
Cell line
(Trichoplusia ni)
Hi5 Invitrogen BTI-TN-5B1-4 Insect cells used for
baculovirus expression
of NbB1
Cell line
(Homo sapiens)
HEK293 ATCC CRL-1573 Mammalian cells used
for Ca2+ signaling assay
Cell line
(Homo sapiens)
HEK293-US28 wt PMID 23303826 Mammalian cells used
for Ca2+ signaling assay
and IP3 assays
Cell line
(Homo sapiens)
HEK293S GnTI- Gift from Prof. H.
Gobind Khorana
(PMID 12370423)
Mammalian cells used for
baculovirus expression
of US28 variants and chemokines
Cell line
(Homo sapiens)
Flp-In TREx 293 Invitrogen R78007 Hamster cells used for
b-arrestin assay
Cell line
(Chinese hamster ovary)
CHO-K1 EA-arrestin DiscoverixRx 93–0164
Transfected construct
(b-arrestin recruitment)
US28 wt/ProLink/b-galactose This report Vector provided by DiscoverixRx
Continued on next page
Figure 5 continued
DOI: https://doi.org/10.7554/eLife.35850.025
The following source data and figure supplement are available for figure 5:
Source data 1. Summary of crystallization and crystallographic statistics.
DOI: https://doi.org/10.7554/eLife.35850.027
Figure supplement 1. Apo- structure and comparison of intracellular faces.
DOI: https://doi.org/10.7554/eLife.35850.026
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers Additional information
Antibody Anti-protein C (mouse IgG1) ATCC HB-9892 Antibody used for staining yeast
bound to protein C tagged target
proteins. Purified from HPC-4 MOUSE
HYBRIDOMA for Alexa647 labeling.
Antibody Anti-FLAG M1
(mouse IgG2a)
Gift from Prof. Brian
Kobilka (PMID 17962520)
Antibody used for US28 purification.
Purified from M1 HYBRIDOMA to
prepare anti-FLAG M1 affinity resin
Antibody Myc-Tag (9B11) Mouse
mAb (Alexa Fluor
488 Conjugate)
Cell Signaling Technology 2279 Antibody used for staining yeast
properly displaying proteins of
interest with Myc-tag
Recombinant DNA
reagent
BestBac Linearized
Baculovirus DNA 2.0,
Exp
ression Systems, 91–002
Expression Systems 554739
Peptide,
recombinant protein
CCL3 Peprotech 300–08
Peptide,
recombinant protein
CCL5 Peprotech 300–06
Peptide,
recombinant protein
CX3CL1 Peprotech 300–31
Commercial
assay or kit
PathHunter b-arrestin
assay
DiscoverixRx
Commercial
assay or kit
MiSeq v2 2  150 Illumina MS-102–2002
Commercial
assay or kit
MiSeq v2 2  250 Illumina MS-102–2003
Chemical
compound, drug
Alexa Fluor 647
NHS Ester (Succinimidyl Ester)
Thermo Fisher
Scientific
A37573 Labeling reagent for
anti-protein C antibody
Chemical
compound, drug
monoolein Sigma M7765 For LCP
Chemical
compound, drug
cholesterol
hemisuccinate tris salt
Anatrace CH210 For membrane protein purification
and yeast staining buffer
Chemical
compound, drug
cholesterol Sigma C8667 For LCP
Chemical
compound, drug
n-dodecyl-b-D-maltoside Anatrace D310 For membrane protein SEC buffer
Chemical
compound, drug
n-dodecyl-b-D-maltoside Anatrace D310S For membrane protein solubilization
buffer, affinity column buffer,
and yeast staining buffer
Software,
algorithm
Prism7 GraphPad
Software,
algorithm
XDS PMID 20124692 Data integration, scaling,
space-group assignment and
merging
Software,
algorithm
Phaser PMID 19461840 Molecular replacement
Software,
algorithm
Phenix suite PMID 20124702 Structure refinement
Software,
algorithm
Coot PMID 20383002 Structural model building
Software,
algorithm
PyMol Schro¨dinger Structural visualization/
figure preparation
Software,
algorithm
Pandaseq PMID 22333067
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers Additional information
Software,
algorithm
Geneious Biomatters
Software,
algorithm
Matlab Mathworks
Software,
algorithm
Cytoscape PMID 14597658 Cluster analysis visualization
Software,
algorithm
Cytobank Cytobank, Inc. Flow cytomettry visualization
Software,
algorithm
KaleidaGraph Synergy Software
Software,
algorithm
Clustering algorithm PMID 24855945
Other CNBr-Activated
Sepharose 4 Fast Flow
GE Healthcare 17098101
Other LS columns Miltenyi 130-042-401
Other Anti-Cy5/Anti-Alexa
Fluor 647 MicroBeads
Miltenyi 130-091-395
Other MidiMACS Magnetic
Separator
Miltenyi 130-042-302
Design and purification of US28-nanobody fusions
US28 was truncated by 10 amino acids at the N-terminus and 44 amino acids at the C-terminus.
Examination of the CX3CL1-US28-nanobody7 structure (PDB: 4xt1) allowed for the design of a linker
between the C-terminus of US28DNDC and the N-terminus of nanobody7 composed of two throm-
bin recognition sites and a six residue Gly-Ser linker. This construct, termed US28Nb7, was deco-
rated with HA signal peptide, an N-terminal FLAG epitope tag and a C-terminal 3C protease site, as
well as C-terminal protein C and 8xHis tags. The same design was used to make a single-chain con-
struct between US28 and nanobody11 (previously demonstrated to be competitive with nanobody7
[Burg et al., 2015]), termed US28Nb11.
US28Nb7 and US28Nb11 were expressed in HEK293S GnTI- cells using BacMam baculovirus
transduction. Baculovirus was added to cells at a density of 2  106 cells ml 1 and culture bottles
were shaken for 24 hr at 37˚C with 5% CO2. After harvesting, cells were washed with PBS supple-
mented with 5 mM EDTA and 1:1000 protease inhibitor cocktail (PIC, Sigma Aldrich, St. Louis MO)
and stored at  20˚C. Cell pellets were thawed and lysed with a Dounce homogenizer in a solution
composed of 20 mM Tris-Cl pH 8.0, 5 mM EDTA, 2 mg ml 1 iodoacetamide, and 1:1000 PIC. The
lysate was centrifuged at 40,000 x g for 1 hr and the membrane pellet was resuspended and rotated
for 2 hr in a solubilization buffer consisting of 10 mM HEPES pH 7.4, 150 mM NaCl (HBS), 1% (w/v)
dodecylmaltoside (DDM), 0.2% (w/v) cholesterol hemisuccinate (CHS), 10% (v/v) glycerol, 2 mg ml 1
iodoacetamide, and cOmplete PIC (Roche, Basel Switzerland).
After centrifugation, 5 ml Ni-NTA resin (Qiagen, Hilden Germany ) per L of initial culture was
added and stirred at 4˚C overnight. The resin was then collected in a column; washed with HBS with
added 0.1% (w/v) DDM, 0.02% (w/v) CHS, 10% (v/v) glycerol, and 20 mM imidazole (wash buffer);
and eluted in wash buffer supplemented to 200 mM imidazole. The eluate was then adjusted to 2
mM CaCl2 and further purified over an anti-FLAG M1 affinity column. The receptor was eluted with
0.2 mg ml 1 FLAG peptide and 5 mM EDTA and further purified by size exclusion chromatography
using a buffer containing HBS, 0.02% (w/v) DDM and 0.004% (w/v) CHS.
US28Nb7 and US28Nb11 ‘competitor’ constructs (used in kinetic selections) were digested with
1:10 (w/w) 3C protease for 2 hr at room temperature to remove the protein C epitope tag prior to
size exclusion chromatography. In DN US28Nb7 (used in nanobody selections and chemokine-bind-
ing assay (Figure 2—figure supplement 2)), the thrombin sites in the linker between US28 and
nanobody7 were replaced with Gly-Ser linkers of equal length and a thrombin site was introduced
with a three amino acid Gly-Ser linker N-terminal to Cys22 of US28. This construct was purified as
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above, digested with 1:100 (w/w) thrombin at 4˚C overnight and cleared over an anti-FLAG M1 affin-
ity column prior to size exclusion chromatography. In all cases, the final protein was concentrated,
aliquoted, and stored frozen before staining experiments.
Creation and staining of yeast display constructs
Chemokines were synthesized as N-terminal fusions to the yeast surface protein Aga2p (IDT, San
Jose CA). Constructs were cloned into the vector pYAL with the Aga2p leader sequence, leaving the
chemokine N-terminus free. The plasmid vector contains a Gly-Ser linker and a Myc epitope tag
between the chemokine and Aga2p. Constructs were then electroporated into electrocompetent
EBY-100 yeast, passaged in synthetic defined medium (SDCAA) and protein expression was induced
in SGCAA pH 4.5 media at 20˚C for 24–60 hr as described (Chao et al., 2006), until maximum Myc
epitope tag staining was observed (typically 40–70% of total population).
A CX3CL1 N-terminal library was prepared by assembly PCR with oligonucleotide primers con-
taining degenerate codons at the first seven amino acids of the chemokine (contiguous with the first
cysteine) (Figure 2—figure supplement 2). The amplicon contained 50 base pairs of homology to
pYAL. The mutagenic CX3CL1 DNA and linearized pYAL vector were co-electroporated into EBY100
yeast to yield a library with 2.0  108 transformants.
Induced yeast displaying chemokine were washed with HBS with added 2 mM CaCl2, 10 mM
maltose, 0.1% (w/v) BSA, 0.02% (w/v) DDM and 0.004% (w/v) CHS (Staining Buffer) and stained with
varying concentrations of the desired receptor construct for 2 hr at 4˚C. The yeast were then washed
with staining buffer and stained with Alexa-647 conjugated anti-protein C antibody and Alexa-488
conjugated anti-Myc antibody (Cell Signaling, Danvers MA) for 15 min at 4˚C. After a final wash,
mean cell fluorescence was measured using FL-1 and FL-4 channels of an Accuri C6 flow cytometer
(BD Biosciences, Franklin Lakes NJ).
Chemokine selection by yeast surface display
For the first round of selection, 2.0  109 yeast (10x the library diversity to ensure full coverage)
induced with SGCAA medium were washed with staining buffer and negatively selected to eliminate
any yeast clones against selecting reagents and magnetic column. Yeast were stained with Alexa-
647 conjugated anti-protein C antibody for 15 min at 4˚C, washed with staining buffer and magneti-
cally labeled with 50 ml anti-Alexa-647 microbeads (Miltenyi, Bergish Gladbach Germany) in staining
buffer for 15 min at 4˚C. Yeast were again washed with staining buffer and unlabeled yeast were iso-
lated by clearing through an LS column (Miltenyi) pre-equilibrated with staining buffer. These cleared
yeast were then washed with staining buffer and stained with 3 nM US28Nb7 or 30 nM US28Nb11
for 2 hr at 4˚C. These concentrations were chosen so that ~10% of the yeast would be bound. The
yeast were then washed with staining buffer and stained with Alexa-647 conjugated anti-protein C
antibody for 15 min at 4˚C. Yeast were washed again with staining buffer and magnetically labeled
with 250 ml anti-Alexa-647 microbeads (Miltenyi) in staining buffer for 15 min at 4˚C. Yeast were
again washed with staining buffer and labeled yeast were isolated by magnetic selection with an LS
column (Miltenyi) pre-equillibrated with staining buffer. Magnetically sorted yeast were resuspended
in SDCAA and cultured at 30˚C.
A second round of magnetic selection was performed for US28Nb11 selected yeast at a concen-
tration of 3 nM target (~10% of post-R1 yeast were now bound at this concentration) so that the
same stringency of selection was now achieved for US28Nb11 as for the first round of US28Nb7
selections. For the final round of selection, a kinetic selection was performed to isolate clones with
the slowest off-rates. Yeast equaling 10x the post-selection diversity after the previous round were
induced in SGCAA medium. Non-specific antibody binders were again cleared as described above
and the yeast were again stained with 3 nM US28Nb7 or US28Nb11 (matching the previous round)
for 2 hr at 4˚C. Following this, the yeast were washed with staining buffer and resuspended in 3 mM
of the nanobody-matched ‘competitor’ construct that lacks a protein C tag (and thus will be dark in
the selection). The yeast were incubated at room temperature for 90 min, after which time they were
washed in staining buffer and stained with Alexa-647 conjugated anti-protein C and Alexa-488 anti-
Myc antibodies for 15 min at 4˚C. Yeast were washed with staining buffer and Alexa-647 positive
yeast with the highest Alexa-647/Alexa-488 ratios were purified using a FACS Jazz cell sorter (BD
Biosciences). Post-sorted yeast were resuspended in SDCAA medium and cultured at 30˚C.
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Chemokine cDNA was prepared from each of the post selection library samples, transformed into E.
coli and sequenced, to confirm sequence convergence.
Deep sequencing of chemokine libraries
Deep sequencing was performed as previously described (Birnbaum et al., 2014). Briefly, pooled
plasmids from 2  107 yeast from each round of selection were isolated via yeast miniprep (Zymo-
prep II kit, Zymo Research, Irvine CA) and used as PCR template to prepare Illumina samples. Ampli-
con libraries were designed as follows: Illumina P5-Truseq read 1-(N8)-Barcode-Chemokine-(N8)-
Truseq read 2-IlluminaP7. N8 was added immediately after both sequencing primers to generate
diversity for low-complexity sequencing reads. The adaptor and barcode sequences were appended
via nested cycles of PCR of the purified plasmids using Phusion polymerase (NEB, Ipswich MA). The
number of cycles for each round of PCR was determined by quantitation on a Bioanalyzer (Agilent,
Santa Clara CA) to protect against over-amplification. Primers were proximal to the library region of
the chemokine to ensure high-quality sequence reads with double coverage. Final PCR products
were run on a 2% agarose gel and purified via gel extraction (QIAGEN). Purified PCR products were
then quantitated, normalized for each barcoded round of selection to be equally represented,
doped with 5–50% PhiX DNA to ensure sufficient sequence diversity for high-quality sequence reads
and run on an Illumina Miseq with 2  150 nt Paired End reads (Illumina, San Diego CA).
To analyze the sequence data, contigs were generated for each paired end read using PANDA-
seq software. The contigs were then deconvoluted into individual rounds of selection and trimmed
to the chemokine sequence using Geneious version 6. The numbers of reads for each unique
sequence were then summed. Sequences were then translated into peptides and any reads that con-
tained stop codons, frameshifts, or mutations outside the library design were omitted from further
analysis. Amino acid frequencies were then calculated for those unique sequences that appear with
10 or greater counts as previously described. Clustering of selected CX3CL1 amino termini was per-
formed for US28Nb7 and US28Nb11 samples after the final kinetic selection for all sequences
appearing greater than 10 copies and connected by a Hamming distance of 6 (1 position variable
allowed) into a network.
Chemokine purification
Individual CX3CL1 library variants (CX3CL1.##) selected for signaling analysis were designed and
expressed as reported previously. Constructs comprised the natural CX3CL1 signal peptide, library
amino acid residues 1–7, and CX3CL1 residues 8–77 under the control of the CMV promoter in the
vector pVLAD6. The C-terminal mucin-like stalk was replaced with a flexible linker (SGSGSAAA) fol-
lowed by a 3C protease site (LEVLFQGP) and human Fc.
CX3CL1.## 3C-Fc were expressed in HEK293S GnTI- cells with BacMam baculovirus transduc-
tion. Baculovirus was added to the cells at a density of 2  106 cells ml 1 and culture bottles were
shaken for 72 hr at 37˚C with 5% CO2. Cells were removed by centrifugation, and the culture super-
natant was filtered and then stirred at 4˚C overnight with 3 ml Ni-NTA resin (Qiagen) per L of super-
natant. The Ni-NTA was then collected by filtration, washed with 20 mM imidazole HBS, and eluted
with 200 mM imidazole HBS. To liberate the chemokine from the Fc, 1:50 (w/w) 3C protease was
added to the eluate and incubated at 4˚C overnight. The sample was then diluted 10x with HBS to
20 mM imidazole and run twice through a Ni-NTA column to clear the Fc and protease. The flow-
through containing the final protein was concentrated, aliquoted, and stored frozen before signaling
experiments.
Cell lines
HEK293 cells were obtained from ATCC (Manassas VA) (CRL-1573), CHO-K1 EA-arrestin cell line
from DiscoverX (Fremont CA) and the Flp-In TREx 293 cell line from Invitrogen (Carlsbad CA). Hi5
cells were from Invitrogen (BTI-TN-5B1-4), SF9 cells were from ATCC (CTL-1711), HEK293GnTI- cells
were provided by Prof. H.G. Khorana, and EBY100 yeast cells were provided by Prof. Dane Wittrup.
Cell line authentication was guaranteed by the sources where the cells were bought. All eukaryotic
cell lines used for signaling and functional assays were tested negative for mycoplasma on a regular
basis, before and during tissue culture.
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Cell culture, US28 constructs, and data analysis for signaling assays
HEK293 cells were grown in Dulbecco´s modified Eagle´s Medium (DMEM) supplemented with 10%
fetal bovine serum (v/v), 180 units mL 1 penicillin and 45 mg mL 1 streptomycin. The CHO-K1 EA-
arrestin2 cells were grown in Ham´s F-12 medium containing 10% fetal bovine serum, 2 mM gluta-
mine, 180 units mL 1 penicillin, 45 mg mL 1 streptomycin and 250 mg mL 1 hygromycin. The stable
clones of inducible US28wt- (parental virus strain TOWNE) HEK293 cells were generated previously
described (Hjortø et al., 2013) and were grown as the following the manufacturer’s protocol for
maintenance of parental and inducible clones (flp-in-t-Rex system, Invitrogen).
The ligands were tested in at least three individual biological replicates, each with at least two
technical replicates. Three biological independent experiments was considered as the minimum
required to see if the results were internally consistent. If the results from one experiment were not
consistent with the two other experiments, the experiment was repeated to gain a minimum of three
independent experiments showing similar results. All experiments were included in the final sum,
except for cases where the controls indicated experimental problems. Experiments were excluded if
the controls indicated experimental problems for example negative data for the positive controls.
Data points were excluded when there was a technical mistake during the procedure of the
experiment.
Radioligand competition binding assay
Stable inducible clones of the US28-cells were seeded in poly-D-lysine (Invitrogen) coated 96-well tis-
sue culture plates (clear plates, Costar). The number of cells seeded was determined by the apparent
expression of receptors and was aimed at obtaining 5–10% binding of the added radioactive ligand.
US28 receptor expression was induced by tetracycline one day after seeding the cells (0.25 mg mL 1;
Invitrogen). 48 hr post seeding, cells were washed twice in ice-cold binding buffer (50 mM HEPES
pH 7.4, supplemented with 1 mM CaCl2, 5 mM MgCl2 and 0.5% (w/v) bovine serum albumin) and
assayed by competition binding for 3 hr at 4˚C using 10–15 pM 125I-CX3CL1, 125I-CCL5, or 125I-CCL3
as well as unlabeled ligand (10 pM to 100 nM in binding buffer). After incubation, cells were washed
twice in ice-cold binding buffer, supplemented with 0.5 M NaCl.
Ca2+ mobilization assay
US28- and HEK293 cells (as a negative control) were seeded at 2  104 cells per well in poly-D-lysine
coated 96-well plates (black, clear bottom, Costar). US28-expression was induced 1 day after seed-
ing by addition of 0.25 mg ml 1 tetracycline. After 24 hr, cells were loaded for 1 hr at 37˚C (5% CO2)
in the dark with 0.2% Fluo-4 (Invitrogen) in loading buffer (19.6 mM HEPES pH 7.4, 1.25 mM proben-
ecid, 1 mM CaCl2, and 1 mM MgCl2). After 1 hr incubation, cells were washed in pre-warmed load-
ing buffer and 100 ml of the loading buffer was added to each well as a final volume. Intracellular
Ca2+ mobilization was monitored upon stimulation with various concentrations of chemokines at
37˚C as fluorescence at excitation and emission wavelengths of 485 and 520 nm, respectively. The
measurements were performed using a FlexStation3 (Molecular Devices, San Jose CA). If used, the
antagonist was incubated in 100 ml loading buffer 10 min prior to the addition of the agonist.
b-arrestin2 recruitment assay
The recruitment of b-arrestin2 was measured using the PathHunter b-arrestin assay (DiscoverX) as
described previously (Daugvilaite et al., 2017). Briefy, cDNA encoding US28wt was fused to the
ProLink C-terminal protein tag and the small fragment ofb-galactose and cloned into pcDNA3.1+.
Assays were performed using the CHO-K1 EA-arrestin cell line with the stable expression of b-galac-
tosidase coupled to the b-gal large fragment. Cells were seeded at 2  104 cells per well and trans-
fected the next day with 50 ng DNA using Fugene6 reagent (0.15 ml per well,
Promega, Madison WI). 48 hr post transfection cells were stimulated with various concentrations of
the chemokine for 90 min (as positive control CCR5 transient transfected cells were included, stimu-
lated with CCL5). b-arrestin2 recruitment was detected as b-gal activity using the PathHunter detec-
tion kit (DiscoverX). Chemiluminescent substrate composed of Galacton Star Substrate, Emerald II
Solution and PathHunter Cell Assay Buffer in a ratio of 1:5:19, respectively, was added to the cells
(50 mL per well). The luminescent signal was determined after 60 min incubation at ambient tempera-
ture using the EnVision Multilabel Plate Reader (PerkinElmer, Waltham MA).
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Cell migration assay
Migration of serum-starved (2 hr) tetracycline induced (16 hr) US28-HEK293 was assessed using
Transwell membranes (Costar; 8 mm pore size). Filters were coated for 30 min at room temperature
on the lower side with 10 mg mL 1 fibronectin (dissolved in PBS; Sigma). The fibronectin solution
was removed and the filters rinsed once with PBS before they were allowed to air-dry. The filters
were placed in a 24-well dish that contained low serum (0.2%) DMEM supplemented with agonists
or control buffer. US28-HEK293 cells suspended in 0.2% serum DMEM (with tetracycline) were
added to the upper chamber (1  105 cells per well). Cells were allowed to migrate for 6 hr at 37˚C.
Non-migrated cells were removed from the top filter surface with a damp cotton swab. Migrated
cells, attached to the bottom surface, were fixed in 3.7% formaldehyde (in PBS) and dyed with crys-
tal violet. Transmigrated cells were counted in five predefined areas on the membrane using a con-
verted light microscope (20x objective; Leica, Wetzlar Germany).
Alpaca immunization
A 3-year-old male alpaca (Lama pacos) was maintained in pasture, and immunized following a proto-
col authorized by the Camelid Immunogenics (Belchertown, MA) and MIT IACUC committees. The
alpaca was immunized by subcutaneous injection of a 1:1 mixture of Imject alum (Thermo
Scientific, Waltham MA) and 800 mg of recombinant US28Nb7 reconstituted in phospholipid vesicles.
After a total of four injections (200 mg each) spaced 2 weeks apart, 50 mL of blood was harvested by
venipuncture and collected into heparinized tubes.
Alpaca nanobody yeast display library construction
Peripheral blood lymphocytes were isolated from total blood by Ficoll-Paque gradients (Ficoll-Paque
Plus, GE Healthcare, Little Chalfont United Kingdom). Total RNA was isolated from ~2106 fresh
peripheral blood lymphocytes (PBLs) using the RNeasy Plus Mini Kit (QIAGEN), following the manu-
facturer’s guidelines. First strand cDNA synthesis was performed using SuperScript III reverse tran-
scriptase (Life Technologies, Carlsbad CA) and a combination of oligo dT, random hexamer or the
immunoglobulin-specific primers AlCH2 and AlCH2.2 (Maass et al., 2007). Nanobody sequences
were then amplified by PCR in two steps for the generation of a yeast display library. PCR products
were ethanol precipitated, and 160 mg of resulting PCR product and 40 mg linearized pCTCON2
vector (Colby et al., 2004) were co-transformed into electrocompetent EBY100 yeast (Invitrogen).
Following transformation, cells were recovered in 1 L SDCAA at 30˚C. Ten-fold serial dilutions were
plated onto SDCAA, grown for 3 days at 30˚C, and colonies were counted to determine library size.
The resulting library was determined to contain 4.8  106 transformants. The library was grown at
30˚C until it reached ten-fold increase over the initial calculated diversity, then pelleted at 3000 x g,
and stored in 10% glycerol at  80˚C.
Nanobody selection by yeast surface display
For the first round of selection, 5  107 yeast displaying the nanobody library were cleared of non-
specific binders to Alexa-647 conjugated anti-protein C antibody as described above for the yeast-
displayed chemokine library. These cleared yeast were then washed with staining buffer and stained
with 1 mM US28Nb7 for 2 hr at 4˚C. Magnetic selection then proceeded as described above for the
yeast displayed chemokine library.
For the second round of selection, two-color FACS was performed. 1  107 induced yeast were
washed with staining buffer and stained with 200 nM US28Nb7DN for 2 hr at 4˚C. The yeast were
then washed with staining buffer and stained with Alexa-647 conjugated anti-protein C and Alexa-
488 conjugated anti-Myc antibodies (Cell Signaling) for 15 min at 4˚C. Yeast were washed again with
staining buffer and the Alexa-647 and  488 double-positive cells were purified using a FACS Jazz
cell sorter (BD Biosciences). Post-sorted yeast were resuspended in SDCAA medium and cultured at
30˚C.
The third round of selection also employed two-color FACS. 1  107 induced yeast were washed
with staining buffer and stained with 10 mM US28Nb11 for 2 hr at 4˚C. The yeast were then washed
with staining buffer and stained with Alexa-647-conjugated anti-protein C and Alexa-488-conjugated
anti-Myc antibodies for 15 min at 4˚C. Yeast were washed again and both double-positive cells and
Alexa-488 singly positive cells were purified separately to distinguish nanobodies that bind both
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US28Nb7 and US28Nb11 from those that are selective. Nanobody cDNA was prepared from each of
the post Round three library samples, transformed into E. coli and sequenced, yielding nanobody
B1.
Nanobody purification
Nanobody B1 was cloned into pAcGP67A insect expression vector (BD Biosciences) with a C-termi-
nal 6xHis tag. Baculovirus was added to High Five cells at a density of 2  106 cell ml 1 and incu-
bated for 60 hr at 28˚C. Collected culture media was conditioned with 50 mM Tris-HCl pH 8.0, 1 mM
NiCl2, 5 mM CaCl2 and the subsequent precipitate was cleared via centrifugation. The media was
then incubated with Ni-NTA resin (QIAGEN) at room temperature for 3 hr and eluted in HBS with
200 mM imidazole. The elution was further purified by size exclusion chromatography before it was
concentrated and aliquoted for future protein complex formation.
CX3CL1.35-US28Nb7-Nb B1 complex purification
CX3CL1.35 was expressed as described for chemokines above. After the initial centrifugation, the
HEK293S GnTI- culture supernatant was filtered and stirred at 4˚C overnight with 10 ml protein A
agarose (Sigma). The protein A agarose was then collected by filtration and washed with HBS.
US28Nb7 was expressed and solubilized as described above. Following centrifugation, protein
A-immobilized CX3CL1.35–3C-Fc was added to the solubilized lysate and mixed by rotating over-
night at 4˚C. The protein A resin was collected by filtration, washed with HBS and incubated at room
temperature for 90 min with ~400 ng 3C protease per liter of initial culture to release the
CX3CL1.35-US28Nb7 complex. Anti-FLAG M1 affinity resin was used to further purify the complex
and remove excess CX3CL1.35. The complex was eluted from the anti-FLAG M1 affinity resin with
0.2 mg ml 1 FLAG peptide and 5 mM EDTA.
Nanobody B1 was added to the CX3CL1.35-US28Nb7 complex at a molar ratio of 1.25:1. The ter-
nary complex was isolated and desalted by size exclusion chromatography using a buffer containing
HBS, 0.02% (w/v) DDM, and 0.004% (w/v) CHS. Complex formation was confirmed by SDS-PAGE.
The complex was then concentrated to 28 mg ml 1, aliquoted, and flash-frozen before crystallization
trials.
US28Nb7 purification
US28Nb7 purification for crystallization proceeded as described above for staining experiments. The
protein was concentrated to 28 mg ml 1, aliquoted, and flash-frozen before crystallization trials.
Crystallization, data collection and structure determination
Crystallization was performed by in meso method with the Gryphon LCP robot (Art Robbins Instru-
ments, ARI, Sunnyvale CA). In the case of CX3CL1.35-US28Nb7-Nb B1, 1:150 (w/w) carboxypepti-
dases A and B (Sigma-Aldrich) were added to each protein aliquot and the mixture was incubated
for 30 min at room temperature to truncate disordered C-terminal residues in situ.
US28Nb7 and CX3CL1.35-US28Nb7-Nb B1 were then reconstituted into LCP by mixing with pre-
pared and pre-warm 10:1 (w/w) monoolein:cholesterol (Sigma-Aldrich) mixture in a 1:1.5 (w/w) pro-
tein:lipid ratio. All samples were mixed with the coupled ARI syringes at least 100 times.
The resulting LCP was dispensed in 20–50 nL onto a glass plate with a 96-well double-sided
spacer tapes. The drops were then overlaid with 650 mL of crystallization buffers summarized in Fig-
ure 5—source data 1 and sealed with a cover glass. Crystals grown at 16˚C or 20˚C in 4–7 days
were harvested using MicroMesh loops (MiTeGen, Ithaca NY) together with the LCP drop, flash fro-
zen and stored in liquid nitrogen. X-ray data collection was performed at Advanced Photon Source
GM/CA beamline 23ID-D. The datasets were initially processed with XDS (Kabsch, 2010). The
phases were determined by molecular replacement using Phaser (McCoy et al., 2007) with the
US28-Nb7 complex and Nb7 with truncation of complementarity determining regions (both are from
PDB: 4xt1) as search models. The structures were further built and fixed using Coot (Emsley et al.,
2010) and refined with Phenix (Adams et al., 2010; Afonine et al., 2012; Echols et al., 2012) using
individual atomic displacement parameters. In the early stages of refinement, reference torsion
restraints were generated (Headd et al., 2012) from the CX3CL1/US28/Nb7 crystal structure (PDB:
4xt1). Data collection and refinement statistics are also summarized in Figure 5—source data 1.
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Atomic contacts were analyzed and structural figures were prepared using
PyMol (Schrodinger, 2010) and structural alignments of the US28 transmembrane helices and other
atomic coordinate transformations were performed using LSQMAN. Software used in this project
was installed and configured by SBGrid (Morin et al., 2013).
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